MEDX Oncology West


Session 7: Integrating Immunotherapy for NSCLC, Melanoma, and Bladder Cancer

Saturday, November 18     8:00am – 10:00am

Description

Immunotherapy is revolutionizing the oncology treatment landscape. As these agents infiltrate the treatment landscape, clinicians are challenged to incorporate new molecular information that can guide treatment selections. This session will address key topics in immunotherapy including the role of the immune system, the nuances involved in biomarker testing, guidance on the incorporation of revised clinical guidelines, and data for approved and emerging agents. Real-world patient cases will emulate optimal selection of immunotherapy for lung, melanoma, and bladder cancer.

Session Outline

Faculty will discuss 3 patient stories to highlight the factors that impact treatment decisions in lung, melanoma, and bladder cancer. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Role of the immune system
  • Mechanisms of action
  • Biomarker testing
  • Current and pending approvals
  • Safety and Efficacy
  • Clinical trials

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 2.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 2.0 hours (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon